Related Experiment Video

Updated: Dec 20, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

Josef Gillson1,2,3, Yogambha Ramaswamy4, Gurvinder Singh4

  • 1Northern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards 2065, NSW, Australia.

Cancers
|May 28, 2020
PubMed

Insights

Targeting KRAS mutations in pancreatic cancer is a new therapeutic strategy. Novel KRAS inhibitors combined with nanoparticle delivery may overcome treatment challenges for pancreatic ductal adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Delivery

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited therapeutic options.
  • Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are key drivers of PDAC.
  • The fibrotic tumor microenvironment impedes effective drug delivery in PDAC.

Purpose of the Study:

  • To review recent advances in targeting mutant KRAS in PDAC.
  • To explore strategies for overcoming drug delivery challenges in PDAC.
  • To propose a novel therapeutic approach for PDAC.

Main Methods:

  • Literature review of recent developments in KRAS inhibitors.
  • Analysis of nanoparticle-based drug delivery systems for cancer therapy.
  • Synthesis of current research on PDAC treatment strategies.

Main Results:

  • Emerging KRAS inhibitors show promise for PDAC treatment.
  • Nanoparticle delivery systems can enhance drug penetration in the fibrotic tumor microenvironment.
  • Combination therapy may improve antitumor efficacy.

Conclusions:

  • Targeting mutant KRAS represents a significant breakthrough in PDAC therapy.
  • Overcoming drug delivery barriers is crucial for effective treatment.
  • The combination of novel KRAS inhibitors and advanced delivery strategies offers a promising therapeutic direction for PDAC.
Keywords:
KRAS inhibitorsanti-fibrotic therapiesdrug deliverynanoparticlespancreatic ductal adenocarcinomatargeted therapies

More Related Videos

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

11.3K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K